Akums Drugs & Pharmaceuticals recently launched its 20th Anniversary Campaign, “BHAROSA – Two Decades of Trust, Going Strong.” A statement from the company informed, “Through the Bharosa Campaign, Akums seeks to raise awareness about its steadfast commitment to sustainability and innovation, both of which align with the company’s long-term vision and core values.”
It also informed, “With a market share of 9.3 per cent of the total addressable Indian domestic CDMO market by value and 8.8 per cent in the IPM market by volume in FY23, Akums has consistently demonstrated its leadership in the domestic CDMO market. Notably, its market share in the Indian domestic CDMO market surged to 29.4 per cent by value in FY23, up from 26.7 per cent in FY21.”
Sanjeev Jain, MD, Akums Drugs & Pharmaceuticals, stated, “April 19, 2004 marks a significant milestone for Akums as we celebrate two decades of longstanding and trusted relationships. Our dedication lies in continuously inspiring and fortifying this trust while cultivating collaborative relationships with all our stakeholders.”
Sandeep Jain, MD, Akums Drugs & Pharmaceuticals, said, “Akums is positioned to contribute to global healthcare solutions. Our 11 operating manufacturing units and four dedicated R&D facilities underscore our commitment to capacity and innovation. Supported by 24 in-house technologies and a team of 332 R&D scientists, we maintain an established track record of excellence in research and development. Looking ahead, our long-term vision for 2030 is to emerge as a global leader in pharmaceutical contract development and manufacturing, while steadfastly upholding our values of trust, excellence, and innovation.”
The post
appeared first on
.It also informed, “With a market share of 9.3 per cent of the total addressable Indian domestic CDMO market by value and 8.8 per cent in the IPM market by volume in FY23, Akums has consistently demonstrated its leadership in the domestic CDMO market. Notably, its market share in the Indian domestic CDMO market surged to 29.4 per cent by value in FY23, up from 26.7 per cent in FY21.”
Sanjeev Jain, MD, Akums Drugs & Pharmaceuticals, stated, “April 19, 2004 marks a significant milestone for Akums as we celebrate two decades of longstanding and trusted relationships. Our dedication lies in continuously inspiring and fortifying this trust while cultivating collaborative relationships with all our stakeholders.”
Sandeep Jain, MD, Akums Drugs & Pharmaceuticals, said, “Akums is positioned to contribute to global healthcare solutions. Our 11 operating manufacturing units and four dedicated R&D facilities underscore our commitment to capacity and innovation. Supported by 24 in-house technologies and a team of 332 R&D scientists, we maintain an established track record of excellence in research and development. Looking ahead, our long-term vision for 2030 is to emerge as a global leader in pharmaceutical contract development and manufacturing, while steadfastly upholding our values of trust, excellence, and innovation.”